This segment focuses on developing treatments for neurological and neuropsychiatric conditions. PureTech utilizes various platforms, including digital therapeutics and small molecule drugs, to address cognitive dysfunction and other neurological disorders. Research and development efforts include clinical trials for LYT-300, an anti-anxiety drug. The company is also developing KarXT, targeting muscarinic acetylcholine receptors for schizophrenia and dementia-related psychosis. This segment aims to improve the lives of patients suffering from debilitating neurological and psychiatric conditions by providing innovative and effective therapies. Market positioning is strengthened by collaborations with leading pharmaceutical companies and the potential for first-in-class treatments. Future opportunities include expanding the pipeline to address a broader range of neurological disorders and leveraging digital health technologies for improved patient monitoring and outcomes.

This segment concentrates on developing therapies for cancer and immune-mediated diseases. PureTech's research and development activities include the development of LYT-200, an IgG4 monoclonal antibody targeting galectin-9, and LYT-210, an IgG1 monoclonal antibody. The company also has collaborations with Boehringer Ingelheim for immuno-oncology product candidates. The segment utilizes immunomodulation platforms to treat chronic and acute inflammatory disorders. The focus is on creating innovative treatments that improve patient outcomes and address unmet medical needs in oncology and immunology. Market positioning is enhanced through strategic partnerships and a focus on developing novel therapies. Future opportunities include expanding the pipeline with new drug candidates and exploring the potential of combination therapies. Regulatory and clinical aspects involve conducting clinical trials and seeking FDA approval for new drug candidates.

This segment is dedicated to developing treatments for lymphatic flow disorders and gastrointestinal diseases. PureTech is developing LYT-100, an oral small molecule drug candidate for lymphedema and other lymphatic flow disorders. The company also utilizes a hydrogel platform technology to treat obesity and other chronic metabolic diseases. Research and development efforts include clinical trials and exploring the potential of lymphatic targeting chemistry platforms. The segment aims to improve the quality of life for patients suffering from these conditions by providing effective and innovative therapies. Market positioning is enhanced through the development of novel drug candidates and strategic partnerships. Future opportunities include expanding the pipeline to address a broader range of lymphatic and gastrointestinal disorders and exploring the potential of new drug delivery technologies.